Shareholders meeting

Date: 21st August, 2026 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock Code : INDOCO Dear Sir/Madam, Sub: Notice of the 79th Annual General Meeting (AGM) and Annual Report 2025-2026 Pursuant to Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), please find enclosed herewith the Notice of the 79th AGM and the Annual Report for the financial year 2025- 26 for your information and records. In compliance with relevant circulars issued by Ministry of Corporate Affairs and the Securities and Exchange Board of India, the Notice of the AGM along with the Annual Report will be sent by email to those Members whose email addresses are registered with the Company / Depository Participant(s). Additionally, the Notice of the AGM and the Annual Report are also being uploaded on the website of the Company at www.indoco.com. Further, in accordance with Regulation 36 of SEBI Listing Regulations, a letter providing web-link for accessing the Annual Report for the financial year 2025-26 is being sent to all those Members who have not registered their email IDs. The schedule of the AGM is set out below: Particulars Details Time and date of AGM 10:30 a.m., IST, Thursday, 17th September, 2026 Mode Video conference and other audio-visual means Final Dividend record date Thursday, 10th September, 2026 Book Closure for the purpose of Friday, 11th September, 2026 to Thursday, 17th September, Dividend and AGM 2026 (both days inclusive) Cut-off date for e-voting Thursday, 10th September, 2026 Commencement of remote e-voting 09:00 a.m., IST, Sunday, 13th September, 2026 End of remote e-voting 05:00 p.m. IST, Wednesday, 16th September, 2026 This is for your information and records. Thanking you, Yours faithfully, For Indoco Remedies Limited Ramanathan Hariharan Company Secretary & Head- Legal ANNUAL REPORT 2025-2026 Healing Lives With Quality & Trust Table Of Contents 1 Corporate Information 1 2 Message From The Top Management 2 3 Global Footprint 4 4 Manufacturing Excellence 6 5 ESG - Environmental, Social & Governance 8 6 Environment 9 7 Social 12 8 Governance 14 9 Milestones Of Recognition 15 15 10 Leaders In Oral Care In India 16 11 New Launches 17 12 Corporate Social Responsibility 18 13 Notice 19 14 Directors’ Report 57 15 Report On Corporate Governance 91 16 Business Responsibility And Sustainability Report 118 17 Management Discussion And Analysis 153 18 Auditor’s Report On Financial Statements (Standalone) 172 19 Balance Sheet (Standalone) 186 20 Statement Of Profit And Loss (Standalone) 187 21 Cash Flow Statement (Standalone) 188 22 Statement For Changes In Equity (Standalone) 190 23 Significant Accounting Policies (Standalone) 191 24 Notes To Financial Statements (Standalone) 205 25 Financial Highlights 256 26 Auditor’s Report On Financial Statements (Consolidated) 260 27 Balance Sheet (Consolidated) 270 28 Statement Of Profit And Loss (Consolidated) 271 29 Cash Flow Statement (Consolidated) 272 30 Statement For Changes In Equity (Consolidated) 274 31 Significant Accounting Policies (Consolidated) 275 32 Notes On Financial Statements (Consolidated) 290 ANNUAL REPORT 2025-2026 Corporate Information Auditors Board Of Directors M/S GOKHALE & SATHE Chartered Accountants 308/309, Udyog Mandir No. 1, 7-C Bhagoji Keer Marg, Mahim, Mumbai 400016. Registrar & Share Transfer Agent MR. SURESH G KARE MS. ADITI PANANDIKAR MR. SUNDEEP V BAMBOLKAR MUFG INTIME INDIA PVT. LTD. Chairman Managing Director Jt. Managing Director C 101, Embassy 247, LBS Marg, Vikhroli (W), Mumbai 400083. Bankers HDFC BANK LTD. ICICI BANK LTD. CITIBANK N. A. SARASWAT CO-OP BANK LTD. MR. ABHIJIT Y GORE DR. (MS.) VASUDHA V KAMAT Independent Director Independent Director DBS BANK INDIA LTD. YES BANK LTD. STANDARD CHARTERED BANK STATE BANK OF INDIA IDBI BANK LTD. EMIRATES NBD BANK (P.J.S.C.) Registered Office MR. AJAY MULGAOKAR MR. SATISH SHENOY Independent Director Independent Director Indoco House, 166 CST Road, Vidyanagari Marg, Kalina, Santacruz East, Mumbai 400098. Tel. No.: +91 22 62871000 / 68791250 Website: www.indoco.com Company Identification Number MR. PRAMOD GHORPADE MR. RAMANATHAN HARIHARAN Chief Financial Officer Company Secretary & Head - Legal CIN: L85190MH1947PLC005913 ANNUAL REPORT 2025-2026 | 1 Dear Shareholders, Message From The Top Management Dear Stakeholders, The global pharmaceutical industry continues to navigate a period of profound transformation. Geopolitical developments, evolving trade policies, regulatory expectations and macroeconomic uncertainties are reshaping the way healthcare businesses operate across the world. While these factors present near-term challenges, they also reinforce the importance of resilient organisations that can adapt with agility, innovate with purpose and consistently uphold the highest standards of quality. India remains one of the most promising pharmaceutical markets globally, driven by scientific capability, manufacturing excellence and an expanding healthcare ecosystem. Yet, as the industry evolves, sustained success will increasingly depend on innovation, operational excellence and the ability to respond to changing market dynamics with speed and discipline. At Indoco, these principles have guided us for decades. As we complete another year of our journey, we are proud of how our teams have translated challenges into opportunities while remaining steadfast in our commitment to patients, healthcare professionals, customers and shareholders. Our performance during FY 2025-26 reflects the strength of this foundation. Across our businesses, we continued to build momentum through focused execution, disciplined investments and a clear strategic direction. Our Domestic Formulations business expanded its portfolio with the launch of several new products, including the introduction of Cyclopam AC, Iceraft Tablets, Triz LM, Sensodent DSP and Sensodent DCP toothpastes in the OTC segment. We also continued our strategic shift towards mass specialities, enabling a more diversified and future-ready portfolio. The growing confidence of the medical fraternity in our brands is reflected in our prescription performance. During the year, Indoco advanced to the 20th position in the IPM, recording 10.94 crore prescriptions and moving ahead of several established industry players. Our Institution division achieved its business targets for the fifth consecutive year, while Rexidin M Forte Gel emerged as the No. 1 dentist-prescribed oral care brand. These ANNUAL REPORT 2025-2026 | 2 Quality has always been at the helm of what we milestones reaffirm the trust that healthcare professionals resilience. The increasing adoption of renewable energy do. The successful completion of the USFDA continue to place in us. through our open-access solar power projects at our inspection at our Patalganga API facility with zero Patalganga and Rabale locations, coupled with focused Quality has always been at the helm of what we do. The observations, along with the successful EU GMP efforts in energy optimisation, reflects our commitment to successful completion of the USFDA inspection at our (European Union Good Manufacturing Practice) lowering our carbon footprint. The EcoVadis Bronze Medal Patalganga API facility with zero observations, along with the inspection of our Goa & Baddi formulation plants awarded to our Patalganga API facility is an encouraging successful EU GMP (European Union Good Manufacturing from the Malta Medicines Authority, Germany - recognition of these efforts and motivates us to further Practice) inspection of our Goa & Baddi formulation plants LAGeSo authority, further demonstrates the elevate our sustainability journey. by the Malta Medicines Authority, Germ [Showing first 8,000 characters — download PDF for full document]